LEGAL BASIC OF BCG-THERAPY FOR BLADDER CANCER IN MUNICIPAL POLYCLINICS
https://doi.org/10.21292/2075-1230-2016-94-10-55-61
Abstract
The article presents brief data from the literature about the history of BCG vaccine development (Bacille bilie' Calmette-Gue'rin), results of meta-analyses aimed at the evaluation of BCG-therapy efficiency in Ta-T1 bladder cancer. Below one can read descriptions of clinical cases when side effects and complications of this method developed according to the literature data and results of authors' personal observations. The main reason of low level of BCG-therapy use in Russia is low awareness of medical workers about the legal grounds for application of this method. The article gives the list of acting legal acts regulating provision of epidemiological safety when applying BCG-therapy and describes the technique for using this method in municipal polyclinics in compliance with the above legal acts.
About the Authors
M. M. Zorina
Novosibirsk Tuberculosis Research Institute
Russian Federation
Russian Federation
Candidate of Medical Sciences, Head of Epidemiology Department, Epidemiologist,
81a, Okhotskaya St., Novosibirsk, 630040
E. V. Kulchavenya
Novosibirsk Tuberculosis Research Institute;
Novosibirsk State Medical University
Russian Federation
Russian Federation
Doctor of Medical Sciences, Professor, Head Researcher of Tuberculosis Department of Novosibirsk State Medical University,
81a, Okhotskaya St., Novosibirsk, 630040
D. P. Kholtobin
Novosibirsk Tuberculosis Research Institute
Russian Federation
Russian Federation
Candidate of Medical Sciences, Urologist of Urological Clinic,
81a, Okhotskaya St., Novosibirsk, 630040
References
1. Kulchavenya E.V., Krasnov V.А., Skornyakov S.N. et al. Current tendencies of epidemiological situation of extrapulmonary tuberculosis. Tub. i Bolezni Legkikh, 2013, no. 12, pp. 34-38. (In Russ.)
2. Kholtobin D.P., Kulchavenya E.V., Brizhatyuk E.V. et al. Two clinical cases of urinary bladder contraction under action of tuberculous mycobacteria of various types. Urologiya, 2012, no. 3, pp. 44-47. (In Russ.)
3. Aust T.R., Massey J.A. Tubercular prostatic abscess as a complication of intravesical bacillus Calmette-Guérin immunotherapy. Int. J. Urol., 2005, vol. 12, no. 10, pp. 920-921.
4. Bohle A., Jocham D., Bock P.R. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J. Urol., 2003, vol. 169, no. 1, pp. 90-95. http://www.ncbi.nlm.nih.gov/pubmed/12478111.
5. Bohle A., Bock P.R. Intravesical bacillus Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology, 2004, vol. 63, no. 4, pp. 682-687.
6. Bulbul M.A., Hijaz A., Beaini M. et al. Tuberculous epididymo-orchitis following intravesical BCG for superficial bladder cancer. J. Med. Liban., 2002, vol. 50, no. 1-2, pp. 67-69.
7. Foster D.R. Miliary tuberculosis following intravesical BCG treatment. Br. J. Radiol., 1997, vol. 70, no. 832, pp. 429,
8. Griggs H., Cammarata S.K. http://www.ncbi.nlm.nih.gov/pubmed/9726755. Chest, 1998, vol. 114, no. 2, pp. 621-623.
9. Gupta R.C., Lavengood R.Jr., Smith J. P. Miliary tuberculosis due to intravesical bacillus Calmette-Guerin therapy. Chest, 1988, vol. 94, no. 6, pp. 1296-1298.
10. Hughes R.A., Allard S.A., Maini R.N. Arthritis associated with adjuvant mycobacterial treatment for carcinoma of the bladder. Ann. Rheum. Dis., 1989, vol. 48, no. 5, pp. 432-434.
11. Kesten S., Title L., Mullen B., Grossman R. Pulmonary disease following intravesical BCG treatment. Thorax, 1990, vol. 45, no. 9, pp. 709-710.
12. Kulchavenya E., Kholtobin D., Filimonov P. (2012) Natural and Iatrogenic Bladder Tuberculosis: Two Cases. Mycobac Dis 2:110. doi:10.4172/2161-1068.1000110.
13. Lamm D.L. Complications of bacillus Calmette-Guérin immunotherapy. Urol. Clin. North. Am., 1992, vol. 19, no. 3, pp. 565-572.
14. Leebeek F.W., Ouwendijk R.J., Kolk A.H. et al. Granulomatous hepatitis caused by Bacillus Calmette-Guerin (BCG) infection after BCG bladder instillation. Gut., 1996, vol. 38, no. 4, pp. 616-618.
15. LeMense G.P., Strange C. Granulomatous pneumonitis following intravesical BCG. What therapy is needed? Chest, 1994, vol. 106, no. 5, pp. 1624-1626.
16. Morales A., Eidinger D., Bruce A.W. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J. Urol., 1976, vol. 116, no. 2, pp. 180-183.
17. Muttarak M., Lojanapiwat B., Chaiwun B., Wudhikarn S. Preoperative diagnosis of bilateral tuberculous epididymo-orchitis following intravesical Bacillus Calmette-Guerin therapy for superficial bladder carcinoma. Australas Radiol., 2002, vol. 46, no. 2, pp. 183-185.
18. Okadome A., Takeuchi F., Ishii T., Hiratsuka Y. Tuberculous epididymitis following intravesical Bacillus Calmette-Guérin therapy. Nippon Hinyokika Gakkai Zasshi, 2002, vol. 93, no. 4, pp. 580-582.
19. Palayew M., Briedis D., Libman M. et al. Disseminated infection after intravesical BCG immunotherapy. Detection of organisms in pulmonary tissue. Chest, 1993, vol. 104, no. 1, pp. 307-309.
20. Rozenblit A., Wasserman E., Marin M. L. et al. Infected aortic aneurysm and vertebral osteomyelitis after intravesical bacillus Calmette-Guérin therapy. AJR. Am. J. Roentgenol., 1996, vol. 167, no. 3, pp. 711-713.
21. Sharma V.K., Sethy P.K., Dogra P.N. et al. Primary tuberculosis of glans penis after intravesical Bacillus Calmette Guerin immunotherapy. Indian J. Dermatol. Venereol. Leprol., 2011, vol. 77, no. 1, pp. 47-50.
22. Shelley M.D., Kynaston H., Court J. et al. A systematic review of intravesical bacillus Calmette-Guerin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int., 2001, vol. 88, no. 3, pp. 209-216. http://www.ncbi.nlm.nih.gov/pubmed/11488731.
23. Shigehara K., Kobori Y., Amano T., Takemae K. Bilateral tuberculous epididymitis after intravesical Bacillus Calmette-Guerin therapy. Hinyokika Kiyo, 2005, vol. 51, no. 12, pp. 839-842.
24. Sylvester R.J., van der Meijden A.P., Lamm D.L. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J. Urol., 2002, vol. 168, no. 5, pp. 1964-1970. http://www.ncbi.nlm.nih.gov/pubmed/12394686
Review
For citations:
Zorina M.M., Kulchavenya E.V., Kholtobin D.P. LEGAL BASIC OF BCG-THERAPY FOR BLADDER CANCER IN MUNICIPAL POLYCLINICS. Tuberculosis and Lung Diseases. 2016;94(10):55-61. (In Russ.) https://doi.org/10.21292/2075-1230-2016-94-10-55-61
Views:
643
Email this article 